Videos and Podcasts
MST Access: Clinical trials on track; news flow ahead
Chris Kallos of MST Access discusses Pharmaxis clinical trial program with CEO Gary Phillips.
Watch the interview here.
MST Financial (“MST”) materials, or any portion thereof, may not be reproduced, sold or redistributed without the prior and written consent of MST. MST Access reports, updates, video interviews and other materials produced by MST Access have generally been engaged and paid by the subject company for ongoing research coverage. Please refer to full disclosures and disclaimers in the company-specific reports.Pharmaxis Quarterly Investor Update- 29 April 2022.
Pharmaxis Ltd (ASX: PXS) released its Quarterly Shareholder Update on the morning of 29 April 2022.
Investors and analysts joined the Company for a virtual investor briefing by chief executive officer Mr Gary Phillips.
The event consisted of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees. You can watch a recording of the presentation here.
Pharmaxis R&D Showcase Webinars - Recordings
Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods.
Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers.
|
Presentation |
Speaker |
Link to recording |
|
Welcome and Introduction to Pharmaxis research and clinical development program |
Michael Woods Dr Wolfgang Jarolimek Gary Phillips |
|
|
The myelofibrosis landscape and MF-101 |
Dr Gabriela Hobbs (Massachusetts General Hospital) |
|
|
Hepatocellular cancer and Rochester University investigator led study |
Dr Paul Burchard (Rochester NY) |
|
|
Pancreatic Cancer |
Dr Tom Cox |
|
|
Pharmaxis Q&A |
Gary Phillips |
Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)
A pdf of the presentations is available here.
Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.
|
Presentation |
Speaker |
Link to recording |
|
Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology |
Gary Phillips |
|
|
The science of scarring and potential for LOX inhibition |
Dr Mark Fear (UWA) |
|
|
Clinical applications for LOX inhibition |
Professor Fiona Wood (UWA) |
|
|
Q&A with panel |
Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)
A pdf of the presentations is available here.
